Get started
Author

Daniel Podzamczer

Observed names: D Podzamczer, D. Podzamczer, Podzamczer, D, Podzamczer, Daniel
Observed institutions: Universitat Autònoma de Barcelona, Janssen (Belgium), Generalitat de Catalunya, Hvidovre Hospital, Bellvitge University Hospital, Rigshospitalet, Hospital General Universitario Gregorio Marañón, IrsiCaixa, Institut d'Investigació Biomédica de Bellvitge, Departament de Salut, University Hospital Mútua de Terrassa, Hospital Universitario 12 De Octubre, Heartlands Hospital, Hospital Universitario Príncipe de Asturias, Hospital Clínic de Barcelona, Vall d'Hebron Hospital Universitari, Hospital Universitario Fundación Jiménez Díaz, Mútua Terrassa, Hospital Universitario de La Princesa, MIB (Germany), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Hospital Sant Jaume de Calella, Hospital Universitari Joan XXIII de Tarragona, Hospital Universitari Germans Trias i Pujol, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació Lluita contra les Infeccions, Janssen Research & Development (United States), The University of Texas Medical Branch at Galveston, Universitat de Barcelona
ORCID: 0000-0001-7090-3561
Observed ORCID: 0000-0001-7090-3561
OpenAlex ID: A5107517502
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
2015 · Paul E Sax, David Wohl, et al. · The Lancet · 615
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
2013 · Francois Raffi, Anita Rachlis, et al. · The Lancet · 561
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
2017 · David A Margolis, Juan Gonzalez-Garcia, et al. · The Lancet · 514
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
2017 · Joel Gallant, Adriano Lazzarin, et al. · The Lancet · 406
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection
2003 · Esteban Martínez, Juan A. Arnaiz, et al. · New England Journal of Medicine · 292
PDF
Brief Report
2015 · Sharon Walmsley, Axel Baumgarten, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 230
Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study
2010 · Frank A Post, Graeme J Moyle, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 216
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
2018 · Jean-Michel Molina, Douglas Ward, et al. · The Lancet HIV · 208
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate
2019 · Samir K. Gupta, Frank A. Post, et al. · AIDS · 179
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent
2011 · Jing Yuan, Sheng Guo, et al. · AIDS · 158
Visceral leishmaniasis in patients infected with human immunodeficiency virus
1990 · C. Montalban, J.L. Calleja, et al. · Journal of Infection · 158
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
2018 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 153
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
2020 · Chloe Orkin, Edwin DeJesus, et al. · The Lancet HIV · 148
PDF
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
2015 · José R Arribas, Pierre-Marie Girard, et al. · The Lancet Infectious Diseases · 147
The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
2015 · José R. Santos, María Saumoy, et al. · Clinical Infectious Diseases · 144
A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study)
2002 · Daniel Podzamczer, Elena Ferrer, et al. · Antiviral Therapy · 137
Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine
2006 · Daniel Podzamczer, Elena Ferrer, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 136
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
2019 · Michael Aboud, Chloe Orkin, et al. · The Lancet HIV · 127
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
2012 · Esteban Martínez, Polyana M. D’Albuquerque, et al. · AIDS · 127
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
2020 · Jesús Rodríguez-Baño, Jerónimo Pachón, et al. · Clinical Microbiology and Infection · 122
A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen
2006 · Margaret A Johnson, Joseph C Gathe, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 118
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine
2005 · Cesar Fisac, Emilio Fumero, et al. · AIDS · 116
Intermittent Trimethoprim-Sulfamethoxazole Compared with Dapsone-Pyrimethamine for the Simultaneous Primary Prophylaxis of Pneumocystis Pneumonia and Toxoplasmosis in Patients Infected with HIV
1995 · Daniel Podzamczer, Albert Salazar, et al. · Annals of Internal Medicine · 116
Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial
2010 · ARTEN investigators, Vicente Soriano, et al. · Antiviral Therapy · 111
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
2021 · Daniel K Nomah, Juliana Reyes-Urueña, et al. · The Lancet HIV · 107
PDF
Works count: 230
Citation count: 8,775
H-index: 43
I10-index: 130
Year
Topic
Type